NEW YORK, May 30 /PRNewswire-FirstCall/ -- The following is being issued by NASDAQ :
What: Samuel E. Lynch, President & CEO of BioMimetic Therapeutics will preside over the closing bell to celebrate its initial public offering on the NASDAQ. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday May 31st, 2006 at 4:00 p.m. EDT Contacts: Kearstin Patterson BioMimetic Therapeutics Corporate Communications 615-236-4419 kpatterson@biomimetics.com NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220 Feed Information: The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8 The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220. Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice. About BioMimetic Therapeutics [BMTI]:
BioMimetic Therapeutics, Inc. develops and commercializes bio-active drug- device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in November 2005 for its first product GEM 21S(R) as a grafting material for bone and periodontal regeneration. A pivotal human clinical trial demonstrated the safety and efficacy of its platform technology in this indication, resulting in significantly faster healing and improved bone healing on clinical X-rays. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. The Company believes its regenerative therapies will improve the treatment options and quality of life for millions of patients with injuries or deterioration of bones, cartilage, tendons or ligaments. For further information, visit http://www.biomimetics.com
NASDAQCONTACT: Kearstin Patterson, Corporate Communications of BioMimeticTherapeutics, +1-615-236-4419, kpatterson@biomimetics.com; or StephanieLowenthal of NASDAQ MarketSite, +1-646-441-5220
